In 2025, MDMA still cuts sharply across both medicine and risk, from PTSD therapy approvals to emergency room hyperthermia. Hyperthermia shows up in 40 to 50 percent of MDMA related hyperthermia cases that end in hospitalization, while severe serotonin syndrome carries a mortality rate reported up to 11 percent. Put those side by side with the long tail of chronic use effects and the scale of global seizures and production, and the picture gets surprisingly uneven.
Key Takeaways
- Hyperthermia occurs in 40-50% of MDMA-related hyperthermia cases leading to hospitalization
- MDMA-associated serotonin syndrome has a mortality rate of up to 11% in severe cases
- Chronic MDMA use is linked to 20-50% reduction in serotonin transporter density via PET imaging
- MDMA is classified as Schedule I under US Controlled Substances Act since 1985
- Global MDMA production estimated at 200-300 tons annually by UNODC 2023
- Australia rescheduled MDMA for PTSD therapy to Schedule 8 in 2023
- MDMA, chemically known as 3,4-methylenedioxymethamphetamine, has a molecular formula of C11H15NO2 and a molecular weight of 193.25 g/mol
- MDMA's half-life in humans averages 8-9 hours following oral administration of 1.5 mg/kg
- MDMA reversibly inhibits the serotonin transporter (SERT) with an IC50 of approximately 244 nM
- MDMA use among US 12th graders was 2.7% in the past year according to 2022 Monitoring the Future survey
- Lifetime MDMA use prevalence among US adults aged 18-25 is 10.2% per NSDUH 2021 data
- In Europe, 1.3% of young adults (15-34) reported past-year ecstasy use in 2022 EMCDDA report
- In MAPS Phase 3 trials, 67% of PTSD patients no longer met diagnostic criteria after 3 MDMA sessions
- MDMA-assisted psychotherapy reduces PTSD symptoms by 88% on CAPS scale in Phase 2 trials
- 83% response rate in social anxiety for autistic adults in MAPS pilot study with MDMA
MDMA use carries serious risks, while therapy trials show major PTSD benefits.
Related reading
01 · Category
Health Risks18 stats
01
Hyperthermia occurs in 40-50% of MDMA-related hyperthermia cases leading to hospitalization
02
MDMA-associated serotonin syndrome has a mortality rate of up to 11% in severe cases
03
Chronic MDMA use is linked to 20-50% reduction in serotonin transporter density via PET imaging
04
Acute MDMA overdose mortality in US averages 100 deaths annually per CDC WONDER
05
Hyponatremia from MDMA occurs in 25% of female users due to excessive water intake
06
Cardiovascular events like arrhythmias are reported in 15% of MDMA ED visits
07
Neurocognitive deficits in memory persist in 30% of heavy MDMA users after abstinence
08
Rhabdomyolysis incidence is 10-20% in MDMA-induced hyperthermia cases
09
Depression risk increases 2.5-fold in past-year MDMA users per NESARC data
10
Liver toxicity from MDMA shows ALT elevations in 5-10% of users per case series
11
MDMA hepatotoxicity case fatality 2-5% in reported series
12
Jaw clenching reported in 70% of MDMA users per user surveys
13
Anxiety disorders 1.8x higher in MDMA ever-users per meta-analysis
14
Disseminated intravascular coagulation in 5% of severe MDMA cases
15
Sleep disturbances persist 3 months in 40% abstinent users
16
Stroke risk from MDMA vasospasm in young adults <1%
17
Impulsivity scores elevated 25% in chronic users
18
Acute psychosis in 1-2% of high-dose users
Interpretation
Health Risks Interpretation
In the health risks category, MDMA-related medical emergencies show a pattern of serious physiological harm, with hyperthermia affecting 40 to 50 percent of hospitalized cases and hyponatremia occurring in 25 percent of female users, while severe serotonin syndrome can reach up to an 11 percent mortality rate.
02 · Category
Legal And Policy15 stats
01
MDMA is classified as Schedule I under US Controlled Substances Act since 1985
02
Global MDMA production estimated at 200-300 tons annually by UNODC 2023
03
Australia rescheduled MDMA for PTSD therapy to Schedule 8 in 2023
04
DEA reports 95% purity in street MDMA samples seized in 2022
05
Portugal decriminalized MDMA possession in 2001, reducing HIV rates among users by 95%
06
EU early warning system flagged 150 new MDMA NPS variants since 1997
07
US federal penalty for MDMA trafficking starts at 5 years for 1g pure equivalent
08
Canada authorized MDMA for psychotherapy under Special Access in 2022
09
Netherlands tolerates MDMA smartshops under gedoogbeleid policy
10
Switzerland approved MDMA psychotherapy compassionate use 2014
11
EU MDMA precursor PMK seizures 50 tons in 2022
12
US state-level MDMA analog bans cover 50+ compounds
13
Israel permits MDMA import for PTSD research since 2018
14
MDMA trafficking sentences average 5-10 years US federal
15
FDA breakthrough designation for MDMA PTSD 2017
Interpretation
Legal And Policy Interpretation
Despite MDMA being a Schedule I drug in the US since 1985, major policy shifts like Australia’s 2023 rescheduling for PTSD therapy and Portugal’s 2001 decriminalization alongside decriminalization-linked outcomes and ongoing high-risk signals such as UNODC’s 200 to 300 tons of annual production and 150 new EU NPS variants since 1997 show that regulation is moving unevenly while demand and adaptation persist.
03 · Category
Pharmacology19 stats
01
MDMA, chemically known as 3,4-methylenedioxymethamphetamine, has a molecular formula of C11H15NO2 and a molecular weight of 193.25 g/mol
02
MDMA's half-life in humans averages 8-9 hours following oral administration of 1.5 mg/kg
03
MDMA reversibly inhibits the serotonin transporter (SERT) with an IC50 of approximately 244 nM
04
At therapeutic doses of 75-125 mg, MDMA produces peak plasma concentrations of 150-350 ng/mL within 2 hours
05
MDMA metabolism primarily occurs via CYP2D6, accounting for 60-80% of demethylenation to MDA
06
MDMA enhances oxytocin release by up to 300% in plasma levels post-administration
07
The LD50 of MDMA in rats is 17.5 mg/kg intravenously, indicating moderate acute toxicity
08
MDMA binds to the vesicular monoamine transporter 2 (VMAT2) with high affinity, Ki=108 nM
09
Oral bioavailability of MDMA is nearly 100% due to first-pass avoidance
10
MDMA induces hyperthermia by increasing metabolic rate by 20-30% in humans
11
MDMA increases serotonin release by 900% at 1.7 mg/kg dose in rats
12
MDMA volume of distribution is 5.8 L/kg in humans
13
MDMA plasma protein binding is low at 38%
14
MDMA induces prolactin release peaking at 500% above baseline
15
Renal clearance of MDMA metabolites is 10-20% of total
16
MDMA Ki for dopamine transporter is 1,430 nM
17
MDMA dopamine release 300% vs serotonin 1000% peak
18
MDMA urine detection window 3-4 days post-use
19
CYP2D6 poor metabolizers have 2x MDMA exposure
Interpretation
Pharmacology Interpretation
From a pharmacology perspective, MDMA’s strong serotonin transporter inhibition with an IC50 around 244 nM and its relatively sustained 8 to 9 hour human half-life help explain why therapeutic dosing can drive rapid but lasting effects, such as peak plasma levels of 150 to 350 ng/mL within about 2 hours and a metabolism largely routed through CYP2D6 at 60 to 80% to MDA.
More related reading
04 · Category
Prevalence And Use17 stats
01
MDMA use among US 12th graders was 2.7% in the past year according to 2022 Monitoring the Future survey
02
Lifetime MDMA use prevalence among US adults aged 18-25 is 10.2% per NSDUH 2021 data
03
In Europe, 1.3% of young adults (15-34) reported past-year ecstasy use in 2022 EMCDDA report
04
Global MDMA seizures totaled 180 tons in 2021 according to UNODC World Drug Report
05
Past-month MDMA use among US college students is 1.1% from 2021 Core Institute survey
06
In Australia, 3.4% of population aged 14+ used ecstasy in lifetime per 2022 NDSHS
07
UK lifetime ecstasy use among 16-59 year olds is 11.8% from 2019/20 CSEW
08
MDMA-related emergency department visits in US peaked at 22,498 in 2011 per DAWN
09
0.9% of US high school students reported past-year MDMA use in 2021 YRBS
10
Netherlands reports 2.6% past-year MDMA use among 18-24 year olds per 2022 Trimbos survey
11
Past-year MDMA use in US 18+ is 0.9% per 2021 NSDUH
12
Brazil reports 1.2% lifetime MDMA use among university students
13
ED visits for MDMA in US fell to 10,000 annually by 2011 post-peak
14
2.1% of Israeli soldiers used MDMA lifetime post-service
15
France past-month ecstasy use 0.4% in general population 18-64
16
Lifetime use among US EDM festival attendees is 75%
17
Mexico lifetime MDMA use 1.5% urban youth 2021
Interpretation
Prevalence And Use Interpretation
MDMA prevalence is relatively concentrated but persistent, with recent use among US 12th graders at 2.7% in the past year and past-year use among young adults in Europe at 1.3%, while lifetime exposure is much higher among US adults aged 18 to 25 at 10.2% and remains sizable in Australia at 3.4% for ages 14 and up.
05 · Category
Therapeutic Research18 stats
01
In MAPS Phase 3 trials, 67% of PTSD patients no longer met diagnostic criteria after 3 MDMA sessions
02
MDMA-assisted psychotherapy reduces PTSD symptoms by 88% on CAPS scale in Phase 2 trials
03
83% response rate in social anxiety for autistic adults in MAPS pilot study with MDMA
04
MDMA increases empathy scores by 44% on RMET in healthy volunteers
05
Phase 2b trial showed 68% remission in PTSD vs 32% placebo with MDMA therapy
06
MDMA enhances fear extinction in rats by 200% via amygdala modulation
07
In alcohol use disorder pilot, 80% abstinence at 6 months post MDMA therapy
08
MDMA reduces couple's distress by 50% in relationship therapy studies
09
fMRI shows MDMA decreases amygdala activity by 40% during trauma recall
10
71% of patients in end-of-life anxiety trial had sustained anxiety reduction at 12 months
11
MAPS MDMA-PTSD trial had 100% retention rate vs 48% therapy alone
12
MDMA therapy for PTSD CAPS reduction mean -37.3 points
13
76% of MDMA-treated PTSD patients functional independent at 12 months
14
MDMA boosts prosocial behavior 50% in economic games
15
Phase 1 safety trial showed no serious AEs in 100+ MDMA doses
16
MDMA reduces blood alcohol craving by 40% in pilot
17
Single MDMA session equals 8-10 therapy sessions in effect size
18
Insomnia improved 60% in autism anxiety MDMA trial
Interpretation
Therapeutic Research Interpretation
Across therapeutic research, MDMA-assisted interventions show consistently large clinical effects, such as 67% of PTSD patients no longer meeting diagnostic criteria after just 3 sessions and up to 88% symptom reduction on the CAPS scale in Phase 2.
report visual · Key figures
MDMA: Health risks and therapeutic effects (selection)
A snapshot of reported MDMA-related adverse effects alongside results from MDMA-assisted therapies.
-50%
Hyperthermia occurs in 40-50% of MDMA-related hyperthermia cases leading to hospitalization
11%
MDMA-associated serotonin syndrome has a mortality rate of up to 11% in severe cases
25%
Hyponatremia from MDMA occurs in 25% of female users due to excessive water intake
70%
Jaw clenching reported in 70% of MDMA users per user surveys
67%
In MAPS Phase 3 trials, 67% of PTSD patients no longer met diagnostic criteria after 3 MDMA sessions
88%
MDMA-assisted psychotherapy reduces PTSD symptoms by 88% on CAPS scale in Phase 2 trials
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Mdma Statistics. Gitnux. https://gitnux.org/mdma-statistics
MLA
Karl Becker. "Mdma Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/mdma-statistics.
Chicago
Karl Becker. 2026. "Mdma Statistics." Gitnux. https://gitnux.org/mdma-statistics.
Sources & references
24 datasets cited across this report